

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
6 December 2007 (06.12.2007)

PCT

(10) International Publication Number
WO 2007/138048 A1

(51) International Patent Classification:

C07D 213/68 (2006.01) A61P 33/06 (2006.01)
A61K 31/44 (2006.01)

(21) International Application Number:

PCT/EP2007/055188

(22) International Filing Date: 29 May 2007 (29.05.2007)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:

06381025.3 31 May 2006 (31.05.2006) EP
07380072.4 8 March 2007 (08.03.2007) EP

(71) Applicant (for all designated States except US): **GLAXO GROUP LIMITED** [GB/GB]; Glaxo Wellcome House, Berkeley Avenue, Greenford Middlesex UB6 0NN (GB).

(72) Inventors; and

(75) Inventors/Applicants (for US only): **BUENO CALDERON, Jose Maria** [ES/ES]; GlaxoSmithKline, Parque Tecnologico de Madrid, Calle Doctor Severo Ochoa, Tres Cantos, E-28760 Madrid (ES). **CHICHARRO GONZALO, Jesus** [ES/ES]; GlaxoSmithKline, Parque Tecnologico de Madrid, Calle Doctor Severo Ochoa, Tres Cantos, E-28760 Madrid (ES). **LORENZO GARCIA, Milagros** [ES/ES]; GlaxoSmithKline, Parque Tecnologico de Madrid, Calle Doctor Severo Ochoa, Tres Cantos, E-28760 Madrid (ES). **MANZANO CHINCHON, M Pilar** [ES/ES]; GlaxoSmithKline, Parque Tecnologico de Madrid, Calle Doctor Severo Ochoa, Tres Cantos, E-28760 Madrid (ES).

(74) Agents: **SARDHARWALA, Fatema** et al.; Glaxo Group Limited, Corporate Intellectual Property CN925.1, 980 Great West Road, Brentford Middlesex TW8 9GS (GB).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, MT, NL, PL, PT, RO, SE, SI, SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:


- as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))
- as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii))
- of inventorship (Rule 4.17(iv))

Published:

- with international search report
- before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(54) Title: NOVEL HETEROCYCLIC COMPOUNDS



(I)

(57) Abstract: 4-pyridone (4-pyridinone) derivatives of Formula I and pharmaceutically acceptable derivatives thereof, processes for their preparation, pharmaceutical formulations thereof and their use in chemotherapy of certain parasitic infections such as malaria, are provided.